medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2014, Number 1

<< Back Next >>

Ann Hepatol 2014; 13 (1)

Anti-HBc positivity was associated with histological cirrhosis in patients with chronic hepatitis C

Coppola N, Gentile I, Pasquale G, Buonomo AR, Capoluongo N, D’Armiento M, Borgia G, Sagnelli E

Language: English
References: 43
Page: 20-26
PDF size: 95.92 Kb.


ABSTRACT

Introduction. In patients with chronic hepatitis C it is still debated whether previous exposure to the hepatitis B virus, diagnosed from the presence of the anti-HBc antibody, is linked to a greater risk of severe hepatitis. The aim of the study was to evaluate whether the presence of anti-HBc antibodies is associated with cirrhosis in patients with HBsAg-negative chronic hepatitis C. Material and methods. Two hundred twenty-two consecutive HBsAg-negative patients with HCV-related chronic hepatitis were enrolled at their first liver biopsy. Ishak’s scoring system was used to grade necroinflammation and fibrosis and the patients with stage 5 or 6 were considered as having histological cirrhosis. Results. Patients with histological cirrhosis had a higher mean age, AST, ALT, a lower platelet count and prothrombin activity compared to those with milder fibrosis. The presence of anti-HBc was identified in 21 (63.6%) of the 33 patients with fibrosis score 5 or 6 and in 56 (29.6%; p ‹ 0.001) of the 189 with score ≤ 4. Patients with cirrhosis had a significantly higher grading than those without cirrhosis (median = 8, IQR 6-11 vs. Median = 6, IQR = 4-8, respectively, p ‹ 0.001). A multivariate logistic regression analysis showed that age, sex and anti-HBc positivity were independent predictors of histological cirrhosis. Conclusion. Our data support the idea that in patients with chronic hepatitis C the presence in serum of anti-HBc is associated with histological cirrhosis and is therefore a marker of clinical value.


REFERENCES

  1. Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 1: 74-81.

  2. Gentile I, Di Flumeri G, Scarica S, Frangiosa A, Foggia M, Reynaud L, Borgia G. Acute hepatitis C in patients undergoing hemodialysis: experience with high-dose interferon therapy. Minerva Urol Nefrol 2013; 65: 83-4.

  3. Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology 1997; 26: 15S-20S.

  4. Gentile I, Viola C, Paesano L, D’Onofrio M, D’Agostino E, Cerini R, Borrelli F, et al. Iron depletion before HCV antiviral therapy: a pilot, randomized, controlled trial. J Clin Apher 2009; 24: 190-6.

  5. Missiha SB, Ostrowski M, Heathcote EJ. Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors. Gastroenterology 2008; 134: 1699-714.

  6. Sagnelli E, Coppola N, Scolastico C, Filippini P, Santantonio T, Stroffolini T, Piccinino F. Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis. Hepatology 2000; 32: 1106-10.

  7. Zampino R, Coppola N, Cirillo G, Boemio A, Pisaturo M, Marrone A, Macera M, et al. Abdominal fat interacts with PNPLA3 I148M, but not with the APOC3 variant in the pathogenesis of liver steatosis in chronic hepatitis C. J Viral Hep 2013; 20: 517-23.

  8. Coppola N, Zampino R, Bellini G, Macera M, Marrone A, Pisaturo M, Boemio A, et al. Association between a polymorphism in cannabinoid receptor 2 and severe necroinflammation in patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2013. In Press. doi: 10.1016/ j.cgh.2013.05.008.

  9. Morisco F, Granata R, Stroffolini T, Guarino M, Donnarumma L, Gaeta L, Loperto I, et al. Sustained virological response: a milestone in the treatment of chronic hepatitis C. World J Gastroenterol 2013; 19: 2793-8.

  10. Gentile I, Borgia G. Surrogate endpoints and non-inferiority trials in chronic viral hepatitis. J Hepatol 2010; 52: 778.

  11. Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, Craxi A, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection: J Hepatol 2008; 49(4): 652-7. doi: 10.1016/ j.jhep.2008.07.014. Epub 2008 Jul 31.

  12. Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999; 341: 22-6.

  13. Sagnelli E, Coppola N, Scolastico C, Mogavero AR, Filippini P, Piccinino F. HCV genotype and “silent” HBV coinfection: two main risk factors for a more severe liver disease. J Med Virol 2001; 64: 350-5.

  14. Paterlini P, Driss F, Nalpas B, Pisi E, Franco D, Berthelot P, Brechot C. Persistence of hepatitis B and hepatitis C viral genomes in primary liver cancers from HBsAg-negative patients: a study of a low-endemic area. Hepatology 1993; 17: 20-9.

  15. Brechot C, Jaffredo F, Lagorce D, Gerken G, Meyer zum Buschenfelde K, Papakonstontinou A, Hadziyannis S, et al. Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe: results of a European concerted action. J Hepatol 1998; 29: 173-83.

  16. Kubo S, Tamori A, Ohba K, Shuto T, Yamamoto T, Tanaka H, Nishiguchi S, et al. Previous or occult hepatitis B virus infection in hepatitis C virus-associated hepatocellular carcinoma without hepatic fibrosis. Dig Dis Sci 2001; 46: 2408-14.

  17. Pollicino T, Squadrito G, Cerenzia G, Cacciola I, Raffa G, Craxi A, Farinati F, et al. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology 2004; 126: 102-10.

  18. Squadrito G, Pollicino T, Cacciola I, Caccamo G, Villari D, La Masa T, Restuccia T, et al. Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients. Cancer 2006; 106: 1326-30.

  19. Sheu JC, Huang GT, Shih LN, Lee WC, Chou HC, Wang JT, Lee PH, et al. Hepatitis C and B viruses in hepatitis B surface antigen-negative hepatocellular carcinoma. Gastroenterology 1992; 103: 1322-7.

  20. Filippini P, Coppola N, Pisapia R, Scolastico C, Marrocco C, Zaccariello A, Nacca C, et al. Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy. AIDS 2006; 20: 1253-60.

  21. Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, Chan HL, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009; 27: 605-11.

  22. Coppola N, Tonziello G, Pisaturo M, Messina V, Guastafierro S, Fiore M, Iodice V, et al. Reactivation of overt and occult hepatitis B infection in various immunosuppressive settings. J Med Virol 2011; 83: 1909-16.

  23. Brechot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini- Brechot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely “occult”? Hepatology 2001; 34: 194-203.

  24. Nan X, Shi S, Yu C, Zhuang H. Meta-analysis of the association between anti-HBc seropositivity and a poor prognosis of chronic HCV infection. Hepatol Res 2010; 40: 1176-87.

  25. Gentile I, Coppola N, Pasquale G, Liuzzi R, D’Armiento M, Di Lorenzo ME, Capoluongo N, et al. A simple noninvasive score based on routine parameters can predict liver cirrhosis in patients with chronic Hepatitis C. Hepatitis Monthly 2013; 13(5): e8352

  26. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9.

  27. Sagnelli E, Pisaturo M, Stanzione M, Messina V, Alessio L, Sagnelli C, Starace M, et al. Clinical presentation, outcomes and response to therapy among patients with acute exacerbation of chronic hepatitis C. Clin Gastroenterol Hepatol 2013. doi:pii: S1542-3565(13)00466-7. 10.1016/ j.cgh.2013.03.025

  28. Gentile I, Viola C, Graf M, Liuzzi R, Quarto M, Cerini R, Piazza M, et al. A simple noninvasive score predicts gastroesophageal varices in patients with chronic viral hepatitis. J Clin Gastroenterol 2009; 43: 81-7.

  29. Gentile I, Thabut D. Noninvasive prediction of oesophageal varices: as simple as blood count? Liver Int 2010; 30: 1091-3.

  30. Sagnelli E, Coppola N, Scolastico C, Mogavero AR, Stanzione M, Filippini P, Felaco FM, et al. Isolated anti-HBc in chronic hepatitis C predicts a poor response to interferon treatment. J Med Virol 2001; 65: 681-7.

  31. Sagnelli E, Imparato M, Coppola N, Pisapia R, Sagnelli C, Messina V, Piai G, et al. Diagnosis and clinical impact of occult hepatitis B infection in patients with biopsy proven chronic hepatitis C: a multicenter study. J Med Virol 2008; 80: 1547-53.

  32. Tonziello G, Pisaturo M, Sica A, Ferrara MG, Sagnelli C, Pasquale G, Sagnelli E, et al. Transient reactivation of occult hepatitis B virus infection despite lamivudine prophylaxis in a patient treated for non-Hodgkin lymphoma. Infection 2013; 41: 225-9.

  33. Fukuda R, Ishimura N, Niigaki M, Hamamoto S, Satoh S, Tanaka S, Kushiyama Y, et al. Serologically silent hepatitis B virus coinfection in patients with hepatitis C virus-associated chronic liver disease: clinical and virological significance. J Med Virol 1999; 58: 201-7.

  34. Coppola N, Pisapia R, Tonziello G, Martini S, Imparato M, Piai G, Stanzione M, et al. Virological pattern in plasma, peripheral blood mononuclear cells and liver tissue and clinical outcome in chronic hepatitis B and C virus coinfection. Antivir Ther 2008; 13: 307-18.

  35. Sagnelli E, Pasquale G, Coppola N, Marrocco C, Scarano F, Imparato M, Sagnelli C, et al. Liver histology in patients with HBsAg negative anti-HBc and anti-HCV positive chronic hepatitis. J Med Virol 2005; 75: 222-6.

  36. Mason AL, Xu L, Guo L, Kuhns M, Perrillo RP. Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigen. Hepatology 1998; 27: 1736-42.

  37. Tanaka T, Inoue K, Hayashi Y, Abe A, Tsukiyama-Kohara K, Nuriya H, Aoki Y, et al. Virological significance of lowlevel hepatitis B virus infection in patients with hepatitis C virus associated liver disease. J Med Virol 2004; 72: 223-9.

  38. Liaw YF, Chen YC, Sheen IS, Chien RN, Yeh CT, Chu CM. Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. Gastroenterology 2004; 126: 1024-9.

  39. Liaw YF, Yeh CT, Tsai SL. Impact of acute hepatitis B virus superinfection on chronic hepatitis C virus infection. Am J Gastroenterol 2000; 95: 2978-80.

  40. Sagnelli E, Coppola N, Messina V, Di Caprio D, Marrocco C, Marotta A, Onofrio M, et al. HBV superinfection in hepatitis C virus chronic carriers, viral interaction, and clinical course. Hepatology 2002; 36: 1285-91.

  41. Sagnelli E, Coppola N, Marrocco C, Onofrio M, Sagnelli C, Coviello G, Scolastico C, et al. Hepatitis C virus superinfection in hepatitis B virus chronic carriers: a reciprocal viral interaction and a variable clinical course. J Clin Virol 2006; 35: 317-20.

  42. Sagnelli E, Coppola N, Pisaturo M, Masiello A, Tonziello G, Sagnelli C, Messina V, et al. HBV superinfection in HCV chronic carriers: a disease that is frequently severe but associated with the eradication of HCV. Hepatology 2009; 49: 1090-7.

  43. Coppola N, Stanzione M, Messina V, Pisaturo M, De Pascalis S, Macera M, Tonziello G, et al. Tolerability and efficacy of anti-HBV nucleos(t)ide analogues in HBV-DNA-positive cirrhotic patients with HBV/HCV dual infection. J Viral Hepat 2012; 19: 890-6.




2020     |     www.medigraphic.com